Alterity Therapeutics Files 6-K, Incorporates AGM Address
Ticker: PRNAF · Form: 6-K · Filed: Nov 22, 2024 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Nov 22, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing-update, agm, registration-statement
Related Tickers: ATHE
TL;DR
Alterity Therapeutics (ATHE) filed a 6-K, incorporating their AGM Chairman's address into existing SEC filings. No new financials, just an update.
AI Summary
Alterity Therapeutics Ltd. filed a Form 6-K on November 22, 2024, to incorporate its 2024 Annual General Meeting Chairman's address into its existing SEC registration statements. This filing does not contain new financial information but serves to update its public filings with the SEC.
Why It Matters
This filing integrates the Chairman's address from the Annual General Meeting into Alterity's SEC registration statements, providing a more complete picture of company communications to investors.
Risk Assessment
Risk Level: low — The filing is a routine administrative update and does not introduce new financial risks or significant operational changes.
Key Players & Entities
- Alterity Therapeutics Ltd. (company) — Registrant
- 2024 Annual General Meeting (event) — Chairman's address incorporated
- Form S-8 (document) — Registration statement referenced
- Form F-3 (document) — Registration statement referenced
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is being filed to incorporate by reference the 2024 Annual General Meeting Chairman's address into Alterity Therapeutics Ltd.'s existing SEC registration statements on Form S-8 and Form F-3.
Does this filing include new financial results for Alterity Therapeutics?
No, this filing does not appear to include new financial results. It primarily serves to incorporate the Chairman's address from the Annual General Meeting.
Which registration statements are being updated by this filing?
This Form 6-K is being incorporated by reference into Alterity Therapeutics Ltd.'s Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, and 333-250076).
What is the former name of Alterity Therapeutics Ltd.?
The former name of Alterity Therapeutics Ltd. was PRANA BIOTECHNOLOGY LTD, with a date of name change on January 5, 2001.
Where is Alterity Therapeutics Ltd. headquartered?
Alterity Therapeutics Ltd. has its principal executive office at Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Filing Stats: 190 words · 1 min read · ~1 pages · Grade level 12.1 · Accepted 2024-11-22 06:58:12
Filing Documents
- ea0222234-6k_alterity.htm (6-K) — 14KB
- ea022223401ex99-1_alterity.htm (EX-99.1) — 12KB
- ex99-1_001.jpg (GRAPHIC) — 9KB
- 0001213900-24-101206.txt ( ) — 40KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 2024 Annual General Meeting Chairman’s address 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: November 22, 2024 2